Patented Technology with FDA Clearance
The AfibAlert® is cleared by the FDA, thus you can have confidence that the device will do what we claim it to do. Some of the testing involved in preparing for the FDA review included running the algorithm used in the AfibAlert® against over 51,000 pre diagnosed ECG strips to determine the accuracy which is over 94%.
Innovation is at the heart of what we do at Lohman Technologies and supported by the patents we have been awarded.
Early on, we believed in the importance of providing patients and physicians the ability to monitor their heart rhythms on a long term basis anywhere and anytime. In addition, we felt it was equally important to provide the patient or user of the device instant feedback. We were successful in patenting our know how in this space with our Long Term Atrial Fibrillation Monitor Patent and our Long Term Cardiac Monitor patent.
As we designed devices, we are always looking for innovative ways to make it easier for patients and physicians to use them. One of our Ease of Use innovations was around the way batteries can be placed in the AfibAlert. Our engineers figured out a non-mechanical way to allow for batteries to be placed in any direction when inserted removing the need to try to see a “+” or “-“ on the inside of a battery compartment. This innovation is recognized in our Low Voltage Polarity Correcting DC to DC Converter Patent.
Our history in innovation around cardiac monitoring goes way back to when we invented memory loop recording to allow event recorders to capture the pre and post ECG recordings from when an event was detected by a patient. We felt it was also important to keep recording while this data was being transmitted to ensure both quality and accuracy in how we captured a patient’s ECG. Our innovations in this area are recognized in our Memory Loop ECG Recorder with Continuous Recording patent.